WORLD HEALTH ORGANIZATION

Gilead Sciences' HIV prevention drug Yeztugo is performing "well ahead of expectations" following its recent US and European launch, with unaided awareness reaching 72% compared to typical industry launch levels.

The BOHEMIA trial, the largest study on ivermectin for malaria to date, demonstrated a 26% reduction in new malaria infections when administered alongside standard bed nets in Kenya.

Venus Remedies secured WHO Good Distribution Practices certification for its Supply Chain Unit-II in Baddi, Himachal Pradesh, following a rigorous independent audit by SGS.

SandboxAQ and iOncologi announced a strategic collaboration to develop a novel high-fidelity mRNA vaccine for glioblastoma, the most aggressive malignant brain tumor in adults.

The World Health Organization has included ziresovir (10mg) from Shanghai Ark Biopharmaceutical in its PADO-RSV priority list, making it the first and only RSV antiviral drug selected for the program.

ViiV Healthcare has expanded its voluntary licensing agreement with the Medicines Patent Pool to allow generic production of cabotegravir for HIV treatment in 133 countries, including all low-income and Sub-Saharan African nations.

The DETECT Hep C Trial, the largest pragmatic clinical trial of HCV screening in emergency departments to date, found that nontargeted screening identified significantly more new hepatitis C infections than targeted screening (relative risk 1.34, P=0.02).

Two Phase 2b clinical trials led by LMU University Hospital Munich demonstrated that sutezolid and delpazolid, both oxazolidinone antibiotics, offer safer alternatives to linezolid for tuberculosis treatment with no cases of nerve damage or blood toxicity observed.

The Indian Council of Medical Research (ICMR) and Panacea Biotec have initiated India's first Phase 3 clinical trial for an indigenous tetravalent dengue vaccine called DengiAll.

Bharat Biotech and GSK announced they will reduce the price of the world's first malaria vaccine RTS,S by more than half to less than $5 per dose by 2028.